Aneesha Ahluwalia1, Liangbo L Shen1, Lucian V Del Priore2. 1. Department of Ophthalmology and Visual Science, Yale University School of Medicine, 40 Temple Street, Suite 1B, New Haven, CT, 06510, USA. 2. Department of Ophthalmology and Visual Science, Yale University School of Medicine, 40 Temple Street, Suite 1B, New Haven, CT, 06510, USA. lucian.delpriore@yale.edu.
Abstract
OBJECTIVE: Prior studies of vision-related quality of life (VRQoL) have examined advanced age-related macular degeneration (AMD) as a single group or focused on neovascular AMD (nAMD), even though advanced AMD can refer to either central geographic atrophy (GA) or nAMD. We compared the natural progression of VRQoL in central GA versus nAMD. METHODS: We included Age-Related Eye Disease Study (AREDS) participants with central GA (n = 206) or nAMD (n = 198) who completed the National Eye Institute Visual Function Questionnaire (NEI-VFQ) between 1997 and 2005. The rate of change of VRQoL was calculated as the slopes of linear models fit to longitudinal individual-level NEI-VFQ scores. Multivariable regressions identified factors associated with experiencing a decline in VRQoL during the study period and cross-sectional VRQoL score. RESULTS: There was a minor decline in VRQoL prior to the development of nAMD but a significantly steeper decline after progression to nAMD (0.49 ± 2.91 vs. 3.30 ± 5.58 NEI-VFQ units/year; p < 0.001). The rates of VRQoL decline were similar before and after the development of central GA (1.99 ± 4.97 vs. 1.68 ± 4.65 NEI-VFQ units/year; p = 0.66). Prior to the development of advanced AMD, the rate of VRQoL decline was greater for participants destined to develop central GA versus nAMD (p = 0.007), while postprogression to advanced disease, the rate was greater in nAMD compared with central GA (p = 0.012). Female gender (odds ratio [OR] 2.61, 95% confidence interval [CI] 1.38-5.06; p = 0.003) and higher baseline VRQoL score (OR 1.03, 95% CI 1.01-1.06; p = 0.006) were independently associated with experiencing a longitudinal decline in VRQoL. CONCLUSION: The natural progression of VRQoL differed in central GA versus nAMD, both before and after the development of advanced disease, suggesting that future studies should consider separating these phenotypes. Females and those with a higher baseline VRQoL were more likely to experience a longitudinal decline in VRQoL following progression to advanced AMD.
OBJECTIVE: Prior studies of vision-related quality of life (VRQoL) have examined advanced age-related macular degeneration (AMD) as a single group or focused on neovascular AMD (nAMD), even though advanced AMD can refer to either central geographic atrophy (GA) or nAMD. We compared the natural progression of VRQoL in central GA versus nAMD. METHODS: We included Age-Related Eye Disease Study (AREDS) participants with central GA (n = 206) or nAMD (n = 198) who completed the National Eye Institute Visual Function Questionnaire (NEI-VFQ) between 1997 and 2005. The rate of change of VRQoL was calculated as the slopes of linear models fit to longitudinal individual-level NEI-VFQ scores. Multivariable regressions identified factors associated with experiencing a decline in VRQoL during the study period and cross-sectional VRQoL score. RESULTS: There was a minor decline in VRQoL prior to the development of nAMD but a significantly steeper decline after progression to nAMD (0.49 ± 2.91 vs. 3.30 ± 5.58 NEI-VFQ units/year; p < 0.001). The rates of VRQoL decline were similar before and after the development of central GA (1.99 ± 4.97 vs. 1.68 ± 4.65 NEI-VFQ units/year; p = 0.66). Prior to the development of advanced AMD, the rate of VRQoL decline was greater for participants destined to develop central GA versus nAMD (p = 0.007), while postprogression to advanced disease, the rate was greater in nAMD compared with central GA (p = 0.012). Female gender (odds ratio [OR] 2.61, 95% confidence interval [CI] 1.38-5.06; p = 0.003) and higher baseline VRQoL score (OR 1.03, 95% CI 1.01-1.06; p = 0.006) were independently associated with experiencing a longitudinal decline in VRQoL. CONCLUSION: The natural progression of VRQoL differed in central GA versus nAMD, both before and after the development of advanced disease, suggesting that future studies should consider separating these phenotypes. Females and those with a higher baseline VRQoL were more likely to experience a longitudinal decline in VRQoL following progression to advanced AMD.
Entities:
Keywords:
Age-related macular degeneration; Geographic atrophy; NEI-VFQ; Neovascular age-related macular degeneration; Vision-related quality of life
Authors: Peggy Orr; Anne M Rentz; Mary Kay Margolis; Dennis A Revicki; Chantal M Dolan; Shoshana Colman; Jennifer T Fine; Neil M Bressler Journal: Invest Ophthalmol Vis Sci Date: 2011-05-18 Impact factor: 4.799
Authors: Larry J Davis; Kenneth B Schechtman; Brad S Wilson; Carol E Rosenstiel; Colleen H Riley; David P Libassi; Ralph E Gundel; Louis Rosenberg; Mae O Gordon; Karla Zadnik Journal: Invest Ophthalmol Vis Sci Date: 2006-02 Impact factor: 4.799
Authors: Raul Velez-Montoya; Scott C N Oliver; Jeffrey L Olson; Stuart L Fine; Hugo Quiroz-Mercado; Naresh Mandava Journal: Retina Date: 2014-03 Impact factor: 4.256
Authors: Emily Y Chew; Traci E Clemons; Elvira Agrón; Robert D Sperduto; John Paul Sangiovanni; Matthew D Davis; Frederick L Ferris Journal: JAMA Ophthalmol Date: 2014-03 Impact factor: 7.389
Authors: Xiangrong Kong; Rupert W Strauss; Artur V Cideciyan; Michel Michaelides; José-Alain Sahel; Beatriz Munoz; Mohamed Ahmed; Ann M Ervin; Sheila K West; Janet K Cheetham; Hendrik P N Scholl Journal: Ophthalmology Date: 2017-05-23 Impact factor: 12.079
Authors: Anne L Coleman; Fei Yu; Kristine E Ensrud; Katie L Stone; Jane A Cauley; Kathryn L Pedula; Marc C Hochberg; Carol M Mangione Journal: Am J Ophthalmol Date: 2010-08-05 Impact factor: 5.258
Authors: SriniVas R Sadda; Usha Chakravarthy; David G Birch; Giovanni Staurenghi; Erin C Henry; Christopher Brittain Journal: Retina Date: 2016-10 Impact factor: 4.256
Authors: Li Ming Dong; Ashley L Childs; Carol M Mangione; Eric B Bass; Neil M Bressler; Barbara S Hawkins; Marta J Marsh; Päivi Miskala; Harrris A Jaffee; Lee A McCaffrey Journal: Am J Ophthalmol Date: 2004-07 Impact factor: 5.258
Authors: Sujata P Sarda; Anne Heyes; Meryem Bektas; Tanvee Thakur; Wendy Chao; Michele Intorcia; Samantha Wronski; Daniel L Jones Journal: Clin Ophthalmol Date: 2021-12-08